EXEL earnings: real EPS beat/miss history, analyst consensus Hold, P/E 17.62. Updated 2026-07-23.
Exelixis (EXEL) Research Hub
Exelixis (EXEL) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 56.12 USD (-3.79%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 17.62, market cap 13.90B. This hub links to the full technical, earnings and options research available for EXEL.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 56.12 USD (-3.79%) |
| 52-week range | 49.97 USD – 59.72 USD |
| Trend regime | Range |
| 14-day RSI | 54.8 (Neutral) |
| Trailing P/E | 17.62 |
| Market cap | 13.90B |
| Dividend yield | 0.00% |
Available research for EXEL
Covered Call on EXEL: how it works, illustrative setup around the real 56.12 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on EXEL: how it works, illustrative setup around the real 56.12 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on EXEL: how it works, illustrative setup around the real 56.12 USD price, max profit/loss, breakeven and when to use it. Educational.
EXEL technical analysis: range, last 56.12 USD, RSI 54.8, 52w range 49.97 USD–59.72 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is EXEL in?
Exelixis (EXEL) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is EXEL in an uptrend or downtrend?
As of 2026-09-11, EXEL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is EXEL's trailing P/E ratio?
EXEL's trailing P/E is 17.62, with a market cap of 13.90B. See the earnings research page for full valuation detail.